![Breakthroughs that change patients’ lives]({"type":"image" , "src" : "/sda/112393/JournalAd-TACD-Pfizer-Leaderboard.jpg"})
References
- Blackshear JL, Odell JA. “Appendage obliteration to reducestroke in cardiac surgical patients with atrial fibrillation”.Ann Thorac Surg 1996; 61: 755–9.
- O’Riordan M. FDA Advisory Panel Votes 7 to 5 to Recommend Approval of Watchman LAA Closure Device.Heartwire (Medscape), April 23, 2009.
- Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P. Percutaneous closure ofthe left atrial appendage versus warfarin therapy for preventionof stroke in patients with atrial fibrillation: A randomisednon-inferiority trial. Lancet 2009; 374: 534–42.
- Sievert H, Lesh MD, Trepels T, Omran H, Bartorelli A, Della Bella P, Nakai T, Reisman M, DiMario C, Block P, Kramer P, Fleschenberg D, Krumsdorf U, Scherer D. Percutaneousleft atrial appendage transcatheter occlusion toprevent stroke in high-risk patients with atrial fibrillation:early clinical experience. Circulation 2002; 105: 1887–9.
- Ostermayer SH, Reisman M, Kramer PH, Matthews RV, Gray WA, Block PC, Omran H, Bartorelli AL, Della BellaP, Di Mario C, Pappone C, Casale P, Moses JW, Poppas A, Williams DO, Meier B, Skanes A, Teirstein PS, Lesh MD, Nakai T, Bayard Y, Billinger K, Trepels T, Krumsdorf U, Sievert H. Percutaneous left atrial appendage transcatheterocclusion (PLAATO system) to prevent stroke in high-riskpatients with non-rheumatic atrial fibrillation: results fromthe international multi-center feasibility trials. J Am CollCardiol 2005; 46: 9–14.82 M. Luykx et al.
![A worldwide pioneer in biotechnology.]({"type":"image" , "src" : "/sda/112403/JournalAd-Amgen-MPU.png"})
![Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.]({"type":"image" , "src" : "/sda/112392/Skyscraper_BristolMyersSquibb.jpg"})